argenx Reports 60% Year-Over-Year Increase in VYVGART Sales
argenx (NASDAQ:ARGX) reported second-quarter product net sales of $1.52 billion, a 60% increase year-over-year and 17% sequentially driven by strong performance from its drug VYVGART. The company also expects key pipeline readouts in the coming quarters.
Tickers: $ARGX